-

Angry@Arthritis Launches 1st Global Osteoarthritis Clinical Trial Locator

Shows Major OA Treatment Clinical Trials and Allows Patients to Sign Up ~ Supports $1 Billion Federal Government ARPA-H NITRO OA Cure Moonshot

ALEXANDRIA, Va.--(BUSINESS WIRE)--Angry@Arthritis, a nonprofit focused on attacking and eliminating Osteoarthritis (OA), today announced OA Fix ~Trials in the Mix, the first global OA developmental treatment analysis and clinical trial locator – https://www.angryarthritis.org/oa-fix-trials-in-the-mix/.

Today, there is no cure or FDA-approved treatment for OA, which is the third most common disability in the U.S. It afflicts one in seven Americans – more than 32 million people. The disease levies a $136 billion annual burden on the U.S. economy.

Designed to empower patients and developers with new insights, the free interactive chart shows viable OA treatments in development, joints where those treatments apply, associated procedure, position in the clinical trial process, and geography (U.S. or overseas). Patients use a single go-to screen to sign up for clinical trials.

Developed by Angry@Arthritis, the chart is the product of 18 months of due diligence, including extensive research and face-to-face meetings with global research and clinical OA experts.

Jason Kim, PhD, vice president of OA research at the Arthritis Foundation, said, “The OA Fix chart is a great start to the fantastic new resource for the OA community. It provides a regularly-updated and consolidated view of promising OA treatments – which would be an easy way for patients to gain visibility and access clinical trials as well."

Dr. Leigh Callahan, director at the Osteoarthritis Alliance, explained, “Currently available medicines and behavioral strategies only help people with OA manage symptoms such as pain and functional limitations. It would be a game changer if we had a disease modifying treatment for OA. Angry@Arthritis and the OA Fix provide a snapshot of upcoming treatments for more than 32 million Americans with OA.”

Angry@Arthritis timed the release of this first OA clinical trial market map with the launch of the new Federal government OA Cure moonshot. In May, the Advanced Project Research Agency for Health (ARPA-H) announced its Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program to cure OA. NITRO funding is speculated at more than $1billion dollars – and the program’s goal is to eliminate OA in five years.

Congressman Gerry Connolly (D-VA) said, “ARPA-H NITRO, with its mission to eliminate osteoarthritis within five years, is a testament to the power and necessity of government-funded research and development. As those efforts continue, it’s on all of us to ensure Americans struggling with OA are aware of upcoming and potential treatment options. OA Fix will go a long way toward educating and empowering the OA community.”

Steve O’Keeffe, founder Angry@Arthritis, commented, “As a patient with OA in multiple joints, I wanted to know more about the most viable developmental cures on the horizon, which treatments might work for the joints where I have the disease, and further, how I can sign up for clinical trials. I couldn’t find it – respectfully, clinicaltrials.gov is impossible to navigate – so, we decided to create that OA treasure map – the OA Fix.”

O’Keeffe added that he applauds ARPA-H NITRO, because as we accelerate to a cure, we need to understand the existing OA treatments in development, evaluate their merits, and find a way to accelerate the clinical trial process.

Congressman Gerry Connolly speaks with Steve O’Keeffe about the OA Fix and ARPA-H NITRO on the Angry@Arthritis podcast – https://www.angryarthritis.org/podcasts/uncle-sam-on-oa-leading-the-charge-on-the-hill/. Find A@A podcast on Spotify and leading streaming sites.

About Angry@Arthritis

Angry@Arthritis is a new 501c3 focused on attacking and eliminating osteoarthritis. We provide the patient’s guide to OA, raise money to fund new cures, and advocate for OA to the U.S. Congress. Visit us at Angry@Arthritis.org

Contacts

Brenda Nashawaty
brenda@nashawaty.com
617.688.3253

Angry@Arthritis


Release Versions

Contacts

Brenda Nashawaty
brenda@nashawaty.com
617.688.3253

More News From Angry@Arthritis

University of Basel Delivers First Biological Implants for Treatment of Cartilage Lesions and Osteoarthritis in Humans

BASEL, Switzerland--(BUSINESS WIRE)--The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans. The procedure called Nasal Chondrocyte Tissue-Engineered Cartilage, or N-TEC, provides an innovative alternative to cure confined knee cartilage lesions as well as to address degenerative OA cases that have to date required knee joint replacements – prosthetics that...

Angry@Arthritis Founder and Osteoarthritis Patient Steve O’Keeffe Applauds ARPA-H Moonshot to Find a Cure as He Works to Eliminate Joint Replacements

ALEXANDRIA, Va.--(BUSINESS WIRE)--Osteoarthritis (OA) cripples 1 in 7 American adults. That’s more than 32 million people – including tech entrepreneur and non-profit Angry@Arthritis founder Steve O’Keeffe. O’Keeffe commented on the announcement of the Advanced Research Projects Agency for Health’s (ARPA-H) new Novel Innovations for Tissue Regeneration in OsteoArthritis (NITRO) program – America’s moonshot to cure OA: “Right now, the only FDA-approved treatment is to cut out and replace OA join...

Global Osteoarthritis Leaders Host OA Innovation Shark Tank Meeting at U.S. Congress to Showcase Promise of New Cures – Call for Increased Federal Funding and Transparency

WASHINGTON--(BUSINESS WIRE)--Marking National Arthritis Awareness Month in May, Angry@Arthritis and the Arthritis Foundation yesterday hosted the annual OA Innovation “Shark Tank” meeting on Capitol Hill to spotlight the promise of new treatments to cure osteoarthritis (OA). As researchers and industry demonstrate the success of OA treatments in clinical trials, the arthritis community is saluting innovation and asking Congress for increased OA funding to help cure this disease that afflicts on...
Back to Newsroom